Canaccord analyst William Plovanic lowered the firm’s price target on DexCom (DXCM) to $99 from $106 and keeps a Buy rating on the shares. The firm said they reported a nice beat on the top line, a miss on GMs and OMs, but in-line operating profits given the revenue upside. More importantly, the guide was disappointing with 2025 revenue lifted to reflect Q3 results with Q4 left unchanged, but GM and adjusted EBITDA guidance lowered as costs related to quality issues continue to impact the P&L.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Dexcom’s Stock Weakness Presents a Buy Opportunity Amid Strong Growth Prospects and Strategic Guidance
- Dexcom Reports Strong Q3 2025 Growth and Raises Guidance
- Dexcom’s Strong Q3 Performance and Future Growth Potential Justify Buy Rating
- Closing Bell Movers: Amazon soars to all-time highs on earnings
- DexCom reports Q3 adjusted EPS 61c, consensus 57c